Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-b179
Abstract: Background: HER2 is a well-established therapeutic target in breast and gastric cancer. Although HER2-targeting therapies are available for HER2-overexpressed breast and gastric cancer, the combination with chemotherapy is still necessary. Recent preclinical and clinical studies… read more here.
Keywords: combination; single agent; her2 targeting; tas0728 ... See more keywords